Recombinant Human FGF-23

Recombinant Human FGF-23

Product No.: F1109

[product_table name="All Top" skus="F1109"]

- -
- -
Alternate Names
Fibroblast Growth Factor-23, ADHR, HPDR2, HYPF, PHPTC
Product Type
Recombinant Protein
Expression Host
NS0 Cells
Species
Human
Applications
ELISA Cap

- -
- -
Select Product Size
- -
- -

Background

Fibroblast growth factor-23 (FGF-23), also known as ADHR and HYPF, is a secreted, non-glycosylated protein and member of the FGF family. The FGF family plays a central role during prenatal development and postnatal growth and regeneration of a variety of tissues, by promoting cellular proliferation and differentiation (1). FGF-23 is mostly expressed in bone and connective tissue and exerts its effects through a ternary complex that includes Klotho and an FGF receptor (FGF R4 or the “c” isoforms of FGF R1 or FGF R3); however, Klotho has a restricted distribution that limits FGF-23 activity (2). This complex is an essential regulator of the renal sodium phosphate co-transporter which is accomplished by modulating SLC34A1 levels (3). FGF-23 also inhibits 1-hydroxylase which is responsible for the conversion of calcifediol to calcitriol (the biologically active form of Vitamin D) (4). It up-regulates EGR1 expression in the presence of KL and acts directly on the parathyroid to decrease PTH secretion. Additionally, FGF-23 negatively regulates osteoblast differentiation and matrix mineralization. FGF-23 was identified by its mutations associated with autosomal dominant hypophosphatemic rickets (ADHR), an inherited phosphate wasting disorder (5). Abnormally high level expression of FGF-23 was found in oncogenic hypophosphatemic osteomalacia (OHO), a phenotypically similar disease caused by abnormal phosphate metabolism (6). Mutations in this gene have also been shown to cause familial tumoral calcinosis with hyperphosphatemia.

Protein Details

Purity
>95% by SDS-PAGE and analyzed by silver stain.
Endotoxin Level
<0.1 EU/µg as determined by the LAL method
Fusion Protein Tag
Histidine Tag
Protein Accession No.
Amino Acid Sequence
ypnaspllgs swgglihlyt atarnsyhlq ihknghvdga phqtiysalm irsedagfvv itgvmsrryl cmdfrgnifg shyfdpencr fqhqtlengy dvyhspqyhf lvslgrakra flpgmnpppy sqflsrrnei plihfntpip rrhtqsaedd serdplnvlk prarmtpapa scsqelpsae dnspmasdpl gvvrggrvnt haggtgpegc rpfakfihhh hhh
N-terminal Sequence Analysis
Tyr25
State of Matter
Lyophilized
Predicted Molecular Mass
The predicted molecular weight of Recombinant Human FGF-23 is Mr 26.1 kDa. However, the actual molecular weight as observed by migration on SDS-PAGE is Mr 29-34 kDa.
Predicted Molecular Mass
26.1
Formulation
This recombinant protein was lyophilized from a 0.2 μm filtered solution in MOPS, sodium sulphate (Na2SO4), ethylenediaminetetraacetic acid (EDTA), and dithiothreitol (DTT).
Storage and Stability
This lyophilized protein is stable for six to twelve months when stored desiccated at -20°C to -70°C. After aseptic reconstitution, this protein may be stored at 2°C to 8°C for one month or at -20°C to -70°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. See Product Insert for exact lot specific storage instructions.
Country of Origin
USA
Shipping
Next Day Ambient
NCBI Gene Bank

References & Citations

1. Yamashita, T. et al. (2000) Biochem. Biophys. Res. Commun. 277:494
2. Frishberg, Y. et al. (2007) J. Bone Miner. Res. 22:235
3. Bowe, AE. et al. (2001) Biochem. Biophys. Res. Commun. 284:977
4. Saito, H. et al. (2005) J. Biol. Chem. 280:2543
5. White, KE. et al. (2001) J. Clin. Endocrinol. Metab. 86:497
6. Shimada, T. et al. (2001) Proc. Natl. Acad. Sci. (USA) 98:6500
Elisa Sandwich Protocol
IMPORTANT Use lot specific datasheet for all technical information pertaining to this recombinant protein.
Products are for research use only. Not for use in diagnostic or therapeutic procedures.